AzTrials
AzTrials

KeratoconusPENTACONNCT01145937

PENTACON Trial: Partial ENdothelial Trepanation in Addition to Anterior Lamellar Keratoplasty in keratoCONus

A study testing PET and DALK in people with Keratoconus, run by UMC Utrecht at 5 sites in Netherlands.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Rationale: Keratoconus is a progressive, non-inflammatory corneal disease in which irregular refractive properties of the cornea result in loss of visual acuity. Treatment is aimed at improving vision, principally using (rigid) contact lenses. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Keratoconus
What is being tested?
PET and DALK
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
14 participants
Where
5 sitesNetherlands
Study dates
Mar 2011to May 2015
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • age equal or above 18 years
  • keratoconus as defined and classified by
  • presence of corneal thinning and protrusion on slit-lamp examination
  • topographic criteria according to KISA% index (>100%)
  • mean corneal curvature map
  • decreased best corrected visual acuity due to corneal scarring or contact lens intolerance

Who cannot join

  • prior corneal surgery, cross linking, refractive surgery or other treatment modalities
  • (localized) corneal thickness < 200 µm
  • associated corneal endothelial disease on specular microscopy as defined by:
  • <1500 endothelial cells per mm2
  • polymegathism > 0.3
  • pleomorphism < 0.6 (all are measurements of endothelial dysfunction)
Show all 9Show fewer
  • gross ophthalmic pathology surpassing keratoconus as cause of decreased visual acuity
  • keratoconus-like disease (keratoglobus, pellucid marginal degeneration)
  • associated corneal anomalies (microcornea, macrocornea, buphthalmos, Peters syndrome, ICE-syndrome etc.)

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

Netherlands5 sites
  • Amphia Ziekenhuis

    Breda, 4819 EV

  • Westfries Gasthuis

    Hoorn, 1620 AR

  • UMCN St. Radboud

    Nijmegen, 6500HB

  • Rotterdam Eye Hospital

    Rotterdam, 3000 LM

  • University Medical Center Utrecht

    Utrecht, 3508 GA

Other trials in Netherlands

About this study

Official title: Pentacon Trial: Partial ENdothelial Trepanation in Addition to Anterior Lamellar Keratoplasty in keratoCONus. A Prospective Multicenter Randomized Controlled Trial

Rationale:

Keratoconus is a progressive, non-inflammatory corneal disease in which irregular refractive properties of the cornea result in loss of visual acuity. Treatment is aimed at improving vision, principally using (rigid) contact lenses. With progression of the disease non-correctable refractive abnormalities and/or corneal scars arise. For these advanced stages of keratoconus, a corneal transplant is the only treatment modality.

Read more

New surgical grafting modalities have been developed to create partial thickness grafts, according to the location of corneal pathology. For keratoconus, transplanting only the anterior corneal lamellae lowers long-term graft rejection rates. We utilize a method to enhance the safety of the grafting procedure while better visual outcomes are expected.

Objective:

To investigate the additional value of partial endothelial trepanation (PET) in an anterior lamellar keratoplasty (ALKP) procedure in terms of efficacy and safety in patients with keratoconus.

Study design:

A randomized controlled interventional trial

Study population:

Patients over 18 years old with keratoconus in whom contact lens correction is unsuccessful and who are not suitable for corneal crosslinking.

Intervention:

Patients will be randomly assigned to corneal grafting techniques; partial endothelial trepanation in addition to an anterior lamellar keratoplasty (i.e. the PET group) or a regular ALKP procedure.

Study outcomes:

Risk of per-operative perforation. Secondary, factors contributing to treatment safety and efficacy.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

There is no extra burden or risk associated with participation in this study. All measurements are part of normal clinical practice. Adequate experience is available with both surgical techniques. Study participation has no effect on donor selection. If partial endothelial trepanation (PET) is associated with lower complication rates and better visual outcomes, this might be beneficial in terms of morbidity.

Read the detailed description

Background:

Keratoconus is a progressive, non-inflammatory corneal disease in which irregular refractive properties of the cornea result in loss of visual acuity. Keratoconus usually arise in adolescence, is bilateral and has an estimated incidence of 1:2000. The aetiology of keratoconus is largely unknown, genetic predispositions are currently under investigation. Treatment is aimed at improving vision, principally using (rigid) contact lenses. With progression of the disease non-correctable refractive abnormalities and/or corneal scars arise. For these advanced stages of keratoconus, a corneal transplant is the only treatment modality.

The first corneal transplant for keratoconus was conducted in 1936 by Ramon Castroviejo in New York's Columbia Presbyterian Medical Centre. Ever since, corneal grafting is subject to many technical developments. For over 70 years, a technique is used in which a circular donor disc is cut with a trephine and sutured in a concordantly prepared recipient, called a perforating keratoplasty (PKP).

With the advent of refractive surgery in the years 1990, equipment appeared to split a cornea in horizontal lamellae. This made partial thickness grafting possible, tailoring grafts according to the nature and location of corneal pathology. For keratoconus, only the anterior part of the cornea needs to be transplanted. The posterior (endothelial) part is particularly involved in graft rejections. The chance of graft rejection decreases significantly when the patient's endothelium is left in place.

For keratoconus, this new treatment modality is called a deep anterior lamellar keratoplasty (DALK). The transplanted anterior corneal thickness is maximized, and the patient retains its own endothelium and Descemet membrane, owing to lower graft rejection rates and less secondary cataract formation.

The biggest drawback of a DALK procedure is the risk of inadvertent peroperative corneal perforation; the lamellae is cut to thick necessitating a conversion to a complete thickness graft similar to an regular PKP. To prevent inadvertent perforation, several techniques are described to dissect the stroma from the posterior lying Descemet membrane and corneal endothelium. Failure and perforation are described in 20-36% of cases though, leaving the patient with an inferior end product and leading to poor surgical predictability.

To circumvent this problem we utilize a method in which, in addition to a anterior lamellar keratoplasty (ALKP), a partial endothelial trepanation (PET) is performed. This technique was first performed by Massimo Busin, Villa Serena Hopsital, Forli, Italy. The endothelium en Descemet are paracentrally and circular loosened, but some tissue bridges are left in place. This 'island' is able to mould to the healthy donor curvature. By doing this, the surgeon can retain a safer graft thickness margin leading to a lowered number of preoperative perforations. The addition of PET is believed to make corneal grafting safer and more predictable.

Research statement/question To investigate the additional value of partial endothelial trepanation (PET) in a anterior lamellar keratoplasty (ALKP) procedure in terms of efficacy and safety in patients with keratoconus, compared in a randomized clinical trial with a regular ALKP procedure.

Primary outcome is:

  • Peroperative corneal perforation;

Secondary study objectives are:

  • Best corrected visual acuity one year post op;
  • Manifest refraction one year post op;
  • Contact lens use (soft/rigid/scleral) or spectacle use;
  • Self-rated improvement questionnaire;
  • Graft rejection rate;
  • Corneal endothelial function one year post op;
  • Correlation of DALK outcomes with atopic constitution.

Significance of this research:

The PENTACON trial is designed to answer questions on new treatment modalities for ophthalmic disease, especially keratoconus. Current available research describes various techniques for a lamellar approach of corneal grafting. Most literature concerns retrospective case series, susceptible to several forms of bias. With our prospective randomized approach we aim to supply more clinical relevant information, especially regarding the risk of inadvertent corneal perforation during surgery.

On theoretical grounds we presume that this new technique has even additional value for more progressive keratoconus patients. In early keratoconus visualization during surgery is generally not a big problem. In progressive keratoconus however, scarring occurs and the Descemet membrane underlying the conus behaves differently. We suppose these factors lead to the high corneal perforation rate of 20%. With partial endothelial trepanation larger safety margins can be used and the biggest gain is to be expected in the progressive keratoconus group.

We plan to store the removed patient corneas in the UMCU Biobank. With the enrollment of patients for our PENTACON trial we will gather a significant amount of keratoconus corneas. In the future, we plan to conduct genetic/histopathologic research on these corneas to achieve a better understanding of the mechanisms underlying ophthalmic disease. Currently, all our effort is projected on starting our treatment trial. These etiological questions will be assessed in a later stage.

Conditions
Keratoconus
Being tested
PET, DALK
Keywords
Keratoconus, Corneal grafting, Corneal transplantation, Anterior Lamellar Keratoplasty
Medical subject headings
Keratoconus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PETProcedure or surgery

    Also called Busin

    Partial Endothelial Trepanation in addition to an anterior lamellar keratoplasty

  • DALKProcedure or surgery

    Also called ALK

    Conventional DALK grafting procedure, with Big Bubble technique according to Anwar et al.

Study groups in NCT01145937
Study groupRoleWhat they receive
PETExperimentalPartial endothelial trepanation in addition to anterior lamellar keratoplasty. The endothelium en Descemet are paracentrally and circular loosened, but some tissue bridges are left in place. This 'island' is able to mould to the healthy donor curvature.
Receives: Procedure: PET
DALKActive comparatorConventional DALK grafting procedure where the Big Bubble technique is used according to Anwar et al.
Receives: Procedure: DALK

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Peroperative corneal perforation

    Peroperative corneal perforation is the biggest drawback of currently utilized grafting procedures (ALKP, 20-30%). Our new technique is believed to be safer, by reducing the number of corneal perforations during surgery. Corneal perforation necessitates converting the procedure to a full-thickness graft with a less favourable long term rejection profile.

    Measured: During Surgery. From start to closure of surgical procedure approx. 2h

Secondary outcomes (6)
  1. Best corrected visual acuity one year post op

    To determine treatment efficacy visual acuity is assessed one year post-op.

    Measured: One year post-op

  2. Manifest refraction one year post op

    Manifest refraction can be grossly altered after corneal grafting procedures. To assess this effect, a manifest refraction one year post-op is obtained.

    Measured: One year post-op

  3. Contact lens use (soft/rigid/scleral) or spectacle use

    To assess the dependency on visual aids after corneal grafting. Residual irregular post-op corneal abnormalities can necessitate (rigid) contact lens wear.

    Measured: one year post-op

  4. Self-rated improvement questionnaire

    To assess patient satisfaction with treatment outcomes, such as visual acuity, residual refraction etc. This will be measured using the Visual Functioning Questionnaire-25 (Dutch edition).

    Measured: One year post-op

  5. Corneal endothelial function one year post op

    To assess corneal endothelial function as a measurement for corneal damage sustained during grafting procedure. Endothelial function plays a role in long term corneal decompensation issues.

    Measured: One year post-op

  6. Graft rejection rate

    Lamellar grafting has proven to lower graft rejection rates. Any graft rejection (endothelial, stromal or epithelial) will be recorded en reported.

    Measured: During one-year follow up period

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jun 2010 (estimated)
  2. Study startMar 2011
  3. Primary completionMay 2015
  4. Study completionMay 2015

Why it stopped: during anticipated study duration trial power was not attained.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
14 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01145937
Sponsor's protocol ID
30756.041.10
Acronym
PENTACON
Status last verified
Dec 2015
First submitted
14 Jun 2010
Last updated
3 Dec 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing PET and DALK in people with Keratoconus, run by UMC Utrecht at 5 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 3 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: during anticipated study duration trial power was not attained.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Peroperative corneal perforation (time frame: During Surgery. From start to closure of surgical procedure approx. 2h). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in